Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing and able to give written informed consent for participation in the study.~2. Clinical diagnosis of Amyotrophic Lateral Sclerosis (ALS).~3. Male or female patients between 18 to 80 years (inclusive).~4. Forced Vital Capacity (FVC) 65% of predicted value for gender, height and age at screening.~5. Evaluated with ALSFRS-R and Norris clinical rating scales for at least the past 4 weeks before study drug administration.~Exclusion criteria~1. Unable to understand information about the study or are expected not to collaborate with the study team.~2. Concurrent serious disease, other than ALS, at the discretion of the nvestigator.~3. Pregnancy.~4. Patients of childbearing potential not willing to use adequate double contraception with less than 1 percentage failure rate after the screening visit until the last visit.~5. Addiction to drugs or alcohol.~6. Confirmed HIV, hepatitis B or hepatitis C.~7. Known bleeding disorders or abnormal bleeding events.~8. Treatment with anticoagulant drugs warfarin and novel oral anticoagulants (NOAC) within the last 14 days prior to screening.~9. Treatment with Riluzole or Lamotrigine within the last 28 days prior to study drug administration.~10. Hypersensitivity to dextran sulfate.~11. Poor venous access.~12. Patients with clinically significant abnormal PK-INR, fibrinogen, von Willebrand factor and activated partial thromboplastin time (APTT) at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ILB (Type: EXPERIMENTAL): ILB treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).